NAVIGATING IPILIMUMAB-INDUCED HYPOPHYSITIS IN ADVANCED HEPATOCELLULAR CARCINOMA: A CLINICAL PERSPECTIVE
Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has marked a significant breakthrough in cancer treatment. Ipilimumab (IPI), an anti-CTLA-4 agent, stands out in this therapeutic landscape. However, its efficacy is not without challenges, among them, immune-related adverse events,...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Galega de Medicina Interna
2025-04-01
|
| Series: | Galicia Clínica |
| Subjects: | |
| Online Access: | https://ojs.galiciaclinica.info/gc/article/view/1434 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|